Nunilo Cremades

List of Publications by Year in Descending Order

49 papers	3,662 citations	31 h-index	55 g-index
55 ext. papers	4,511 ext. citations	8.7 avg, IF	5.05 L-index

#	Paper	IF	Citations
49	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.. *Cellular and Molecular Life Sciences*, **2022**, 79, 174	10.3	3
48	The release of toxic oligomers from -synuclein fibrils induces dysfunction in neuronal cells. *Nature Communications*, **2021**, 12, 1814	17.4	39
47	-Helical peptidic scaffolds to target -synuclein toxic species with nanomolar affinity. *Nature Communications*, **2021**, 12, 3752	17.4	5
46	The role of water in the primary nucleation of protein amyloid aggregation. *Biophysical Chemistry*, **2021**, 269, 106520	3.5	13
45	All-or-none amyloid disassembly via chaperone-triggered fibril unzipping favors clearance of -synuclein toxic species. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
44	The extent of protein hydration dictates the preference for heterogeneous or homogeneous nucleation generating either parallel or antiparallel -sheet -synuclein aggregates. *Chemical Science*, **2020**, 11, 11902-11914	9.4	9
43	Multiplicity of -Synuclein Aggregated Species and Their Possible Roles in Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
42	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. *Communications Biology*, **2020**, 3, 435	6.7	23
41	Defining -synuclein species responsible for Parkinson's disease phenotypes in mice. *Journal of Biological Chemistry*, **2019**, 294, 10392-10406	5.4	55
40	Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of -Synuclein Protect Against Diverse -Synuclein Mediated Dysfunctions. *Scientific Reports*, **2019**, 9, 16947	4.9	14
39	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. *Neurobiology of Disease*, **2018**, 109, 178-190	7.5	51
38	Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. *Journal of Parkinson's Disease*, **2018**, 8, 303-322	5.3	80
37	Preparation of -Synuclein Amyloid Assemblies for Toxicity Experiments. *Methods in Molecular Biology*, **2018**, 1779, 45-60	1.4	8
36	Multistep Inhibition of -Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine. *ACS Chemical Biology*, **2018**, 13, 2308-2319	4.9	52
35	A natural product inhibits the initiation of -synuclein aggregation and suppresses its toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E1009-E1017	11.5	177
34	Inhibition of -Synuclein Fibril Elongation by Hsp70 Is Governed by a Kinetic Binding Competition between -Synuclein Species. *Biochemistry*, **2017**, 56, 1177-1180	3.2	45
33	Structural Characteristics of -Synuclein Oligomers. *International Review of Cell and Molecular Biology*, **2017**, 329, 79-143	6	57

32	Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. *Science*, **2017**, 358, 1440-1443	33.3	301
31	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. *ACS Chemical Neuroscience*, **2016**, 7, 399-406	5.7	75
30	Ca2+ is a key factor in α-synuclein-induced neurotoxicity. *Journal of Cell Science*, **2016**, 129, 1792-801	5.3	106
29	Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E1206-15	11.5	130
28	Amyloid-β and α-Synuclein Decrease the Level of Metal-Catalyzed Reactive Oxygen Species by Radical Scavenging and Redox Silencing. *Journal of the American Chemical Society*, **2016**, 138, 3966-9	16.4	52
27	Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. *Antioxidants and Redox Signaling*, **2016**, 24, 376-91	8.4	192
26	Ca2+ is a key factor in α-synuclein-induced neurotoxicity. *Development (Cambridge)*, **2016**, 143, e1.1-e1.1	6.6	3
25	Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1994-2003	11.5	278
24	Fast flow microfluidics and single-molecule fluorescence for the rapid characterization of α-synuclein oligomers. *Analytical Chemistry*, **2015**, 87, 8818-26	7.8	65
23	Cell surface localised Hsp70 is a cancer specific regulator of clathrin-independent endocytosis. *FEBS Letters*, **2015**, 589, 2747-53	3.8	30
22	Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants. *Scientific Reports*, **2015**, 5, 16696	4.9	69
21	Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. *PLoS ONE*, **2014**, 9, e87133	3.7	98
20	Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. *Journal of Molecular Biology*, **2013**, 425, 2397-411	6.5	66
19	Hsp70 oligomerization is mediated by an interaction between the interdomain linker and the substrate-binding domain. *PLoS ONE*, **2013**, 8, e67961	3.7	60
18	Insights in the (un)structural organization of Bacillus pasteurii UreG, an intrinsically disordered GTPase enzyme. *Molecular BioSystems*, **2012**, 8, 220-8		40
17	Direct observation of the interconversion of normal and toxic forms of α-synuclein. *Cell*, **2012**, 149, 1048-59	36.2	588
16	Population of nonnative states of lysozyme variants drives amyloid fibril formation. *Journal of the American Chemical Society*, **2011**, 133, 7737-7743	16.4	67
15	Local cooperativity in an amyloidogenic state of human lysozyme observed at atomic resolution. *Journal of the American Chemical Society*, **2010**, 132, 15580-8	16.4	49

14	Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. *Journal of Molecular Biology*, **2010**, 402, 326-43	6.5	119
13	On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. *Biochemistry*, **2009**, 48, 8322-34	3.2	84
12	Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. *ACS Chemical Biology*, **2009**, 4, 928-38	4.9	39
11	Molten globule and native state ensemble of Helicobacter pylori flavodoxin: can crowding, osmolytes or cofactors stabilize the native conformation relative to the molten globule?. *Biophysical Journal*, **2008**, 95, 1913-27	2.9	17
10	The flavodoxin from Helicobacter pylori: structural determinants of thermostability and FMN cofactor binding. *Biochemistry*, **2008**, 47, 627-39	3.2	28
9	Conformational stability of Helicobacter pylori flavodoxin: fit to function at pH 5. *Journal of Biological Chemistry*, **2008**, 283, 2883-95	5.4	12
8	Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. *Journal of Clinical Investigation*, **2008**, 118, 2858-67	15.9	119
7	Common conformational changes in flavodoxins induced by FMN and anion binding: the structure of Helicobacter pylori apoflavodoxin. *Proteins: Structure, Function and Bioinformatics*, **2007**, 69, 581-94	4.2	22
6	Flavodoxin:quinone reductase (FqrB): a redox partner of pyruvate:ferredoxin oxidoreductase that reversibly couples pyruvate oxidation to NADPH production in Helicobacter pylori and Campylobacter jejuni. *Journal of Bacteriology*, **2007**, 189, 4764-73	3.5	52
5	Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 868-76	5.9	167
4	The native-state ensemble of proteins provides clues for folding, misfolding and function. *Trends in Biochemical Sciences*, **2006**, 31, 494-6	10.3	29
3	Filling small, empty protein cavities: structural and energetic consequences. *Journal of Molecular Biology*, **2006**, 358, 701-12	6.5	21
2	Towards a new therapeutic target: Helicobacter pylori flavodoxin. *Biophysical Chemistry*, **2005**, 115, 267-76	3.5	37
1	Alpha-Synuclein1-12		